Business, energy, technology, markets and global industry news from Business News Today

American Academy of Dermatology

PharmaDeviceNews American Academy of Dermatology
A clinician examines atopic dermatitis symptoms as Bambusa Therapeutics reports preliminary proof-of-concept results for investigational bispecific antibody BBT001. Representative image.
Pharma & Biotech

Could BBT001 quarterly dosing differentiate Bambusa in the atopic dermatitis biologics market?

Bambusa’s BBT001 produced an early atopic dermatitis signal, but larger trials must confirm safety, durability and quarterly dosing.

Read More
A dermatologist evaluates atopic dermatitis during a clinical consultation as Organon’s Phase 3 pooled analysis shows early, consistent improvements with VTAMA tapinarof cream across pediatric age groups and adults. Representative image.
Pharma & Biotech

Organon VTAMA analysis shows consistent atopic dermatitis efficacy across children and adults

Organon’s VTAMA Phase 3 analysis shows consistent atopic dermatitis responses across children and adults, strengthening its clinical case.

Read More
Pharma & Biotech

Why Incyte’s povorcitinib 54-week results matter for hidradenitis suppurativa treatment

Incyte's povorcitinib reaches 71.4% HiSCR50 at 54 weeks in HS. Analysis of what the STOP-HS data mean for the JAK1 class and the treatment landscape.

Read More